Additional Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60611
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    New York NY. 10027
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Richmond VA. 23284
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Miami FL. 33146
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Dallas TX. 75204
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Oklahoma City OK. 73104
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Chicago IL. 60612
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Charleston SC. 29425
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Los Angeles CA. 90024
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    Cleveland OH. 44195
    View Details

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    aTyr Investigative Site
    New Orleans LA. 70115
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Miami FL. 33144
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Los Angeles CA. 90301
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Jacksonville FL. 32610
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    New York NY. 11201
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Denison TX. 75020
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    El Paso TX. 79902
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Philadelphia PA. 19104
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Ann Arbor MI. 48109
    View Details